Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Published:2020-06 Issue:6 Volume:21 Page:763-775
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tolaney Sara M,Wardley Andrew M,Zambelli Stefania,Hilton John F,Troso-Sandoval Tiffany A,Ricci Francesco,Im Seock-Ah,Kim Sung-Bae,Johnston Stephen RD,Chan Arlene,Goel Shom,Catron Kristen,Chapman Sonya C,Price Gregory L,Yang Zhengyu,Gainford M Corona,André Fabrice

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Breast cancer epidemiology, prevention, and screening;Winters;Prog Mol Biol Transl Sci,2017

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group;Marty;J Clin Oncol,2005

5. A systematic review of dual targeting in HER2-positive breast cancer;Kümler;Cancer Treat Rev,2014

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Treatment Sequence in Patients With Stage III Breast Cancer;Journal of Surgical Research;2024-10

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. Clinical Outcomes and Efficacy of Human Epidermal Growth Factor Receptor 2–Targeted Therapy in Breast Cancer With Uncommon In Situ Hybridization Patterns or Discordant Immunohistochemistry;JCO Oncology Advances;2024-09

4. The radiologist’s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review;Insights into Imaging;2024-08-01

5. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24